Meeting
2011 ASCO Annual Meeting
Phase I trial of weekly and every 3 weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs).
Authors
M. Kittaneh
University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
M. Kittaneh , A. J. Montero , K. Kovacs , V. D. Guardiola Amado , A. M. Flores , A. Ferrell , M. Vulfovich , M. D. Pegram , P. W. Benedetto , C. M. S. Rocha Lima , J. R. Merchan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Angiogenesis
Clinical Trial Registration Number
NCT00884676
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3081)
Abstract #
3081
Poster Bd #
16F
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors.
First Author: David Sommerhalder
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan
Poster
2018 ASCO Annual Meeting
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).
First Author: Andrew J. Wagner